Hims & Hers
A consumer telehealth brand that exited compounded semaglutide for new patients following a settlement with Novo Nordisk, and now separates its recurring membership fee from a separate charge for whichever brand-name medication is prescribed.
This is not a review
We have not personally used Hims & Hers, so we are not rating quality of care, wait times, or customer service. What follows is Hims & Hers’s own published terms, checked against independent reporting where we found it. See our full methodology on the provider directory.
Hims & Hers previously offered compounded semaglutide and drew public criticism from Novo Nordisk over how it was marketed, before the March 2026 settlement ended that practice for new patients.
Source: Hims & Hers newsroomAt a glance
- Access model
- Brand-name only
- Medications offered
- Wegovy (pen and pill)Zepbound (KwikPen and vial)FoundayoOzempic (pill)
- Prescriber
- Licensed clinicians via telehealth evaluation
- Insurance
- Primarily cash-pay; membership does not guarantee a prescription
- Membership / program fee
- $39 first month, $149/month thereafter (clinical membership, billed separately from medication)
- Cash-pay from
- Medication from $149–$399/month depending on product and dose
- States served
- Not published in a single state-coverage list — confirm at signup
What that adds up to
Adding Hims & Hers's published figures together — $149 membership plus $149 medication — comes to $298 a month on its clinical membership plus a brand-name medication.
A membership figure and a medication figure are two different numbers, and the one a provider leads with is usually the smaller of the two. We add both together for every provider in this directory and set the result beside buying direct from the manufacturer, on priced against every other route to a GLP-1.
On compounding
Settled with Novo Nordisk on 9 March 2026 and exited compounded semaglutide for new patients; now prescribes FDA-approved brand-name products.
For the fuller regulatory picture — the pending FDA proposal on 503B compounding and what it does and doesn’t affect — see the compounding explainer that sits above every provider we list, Hims & Hers included.
Questions people ask before signing up
Every answer below states only what Hims & Hers publishes about itself, read on 2026-07-26, plus what is on the public record. We have not used this service and we do not rate it.
- Who writes the prescription at Hims & Hers?
- Licensed clinicians via telehealth evaluation. Every GLP-1 receptor agonist is prescription-only in the United States, so a service that supplies one without an assessment is not operating lawfully, whatever it calls itself. This is Hims & Hers's own published description of who evaluates you, read on 2026-07-26.
- Does Hims & Hers use compounded medication?
- No. Its published offer is brand-name only: Wegovy (pen and pill), Zepbound (KwikPen and vial), Foundayo, Ozempic (pill). That means the medication itself is an FDA-approved product, which is the main thing a compounded route does not give you.
- What does Hims & Hers actually cost per month?
- Adding Hims & Hers's published figures together — $149 membership plus $149 medication — comes to $298 a month on its clinical membership plus a brand-name medication. A membership or programme fee and a medication price are two different numbers, and the one a provider leads with is usually the smaller. We add both together for every provider in this directory rather than repeating the advertised figure.
- Does Hims & Hers take insurance?
- Primarily cash-pay; membership does not guarantee a prescription. Whether your own plan covers a GLP-1 at all is a separate question from whether a provider will bill it, and it is usually the one that decides the price — many employer plans exclude weight-management medications as a category.
- Is Hims & Hers available in my state?
- Not published in a single state-coverage list — confirm at signup. Where a provider does not publish a state list we say so rather than assume nationwide coverage, and this field is read from Hims & Hers's own site on 2026-07-26.
- Has Hims & Hers been subject to litigation or regulatory action?
- Hims & Hers previously offered compounded semaglutide and drew public criticism from Novo Nordisk over how it was marketed, before the March 2026 settlement ended that practice for new patients. We record what is on the public record with a source, and we do not characterise it. An allegation is an allegation until a court says otherwise, and where a case has been dismissed we say that too.
How to reach Hims & Hers
Visit Hims & Hers’s own site to confirm current pricing, state availability, and eligibility — all of the figures above can change without notice, and only the provider itself has the current version.
Disclosure We earn nothing from this link. We hold no referral, affiliate, or advertising arrangement with this provider, and this listing was compiled from their own published terms. How we’re funded.
How this compares
Other providers with a similar access model or worth contrasting against:
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- Hims & Hers — published termsHims & HersSupports: Access model, medications, prescriber type, insurance, pricing, and state coverage as stated in this profile.
- Hims & Hers previously offered compounded semaglutide and dr…Hims & Hers newsroomSupports: The regulatory or litigation flag noted above.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.